Oorsprong van het eerstegraads netwerk van Chris Kiefer
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
15
| Subsidiary | Pharmaceuticals: Major | 15 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Chris Kiefer via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AKSYS LTD. | Financial Conglomerates | Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
| AVANIR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director of Finance/CFO General Counsel | |
| MOMENTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Cempra Pharmaceuticals, Inc.
 Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Amherst College | College/University | Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree | |
| Concordia University | College/University | Undergraduate Degree | |
| Davidson College | College/University | Undergraduate Degree | |
| University of London | College/University | Doctorate Degree | |
| The Johns Hopkins University | College/University | Undergraduate Degree | |
| Loyola University Maryland, Inc. | College/University | Undergraduate Degree | |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Digi-Key Corp. distributes electronic components. It also distributes semiconductors, discrete, electromechanical parts. Its products include audio products, batteries, cable assemblies, capacitors, computer & video accessories, connectors, crystals & oscillators, discrete semiconductor products and many more. The company was founded by Ronald A. Stordahl in 1972 and is headquartered in Thief River Falls, MN. | College/University | Undergraduate Degree | |
| The University of North Carolina at Chapel Hill | College/University | Doctorate Degree | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
Satellite Healthcare, Inc.
 Satellite Healthcare, Inc. Medical/Nursing ServicesHealth Services Satellite Healthcare, Inc. is a non-profit, community benefit organization that provides medical services to patients with chronic kidney disease. The company operates dialysis center and provides training and support for patients performing dialysis at home. It also offers pre-dialysis patient wellness education programs that can help prevent or slow the progression of early stage chronic kidney disease. It was founded by Norman S. Coplon in 1973 and is headquartered in San Jose, CA. | Medical/Nursing Services | Director/Board Member | |
| University of Cardiff | College/University | Undergraduate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Otsuka America Pharmaceutical, Inc.
 Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | Pharmaceuticals: Major | Director/Board Member | |
| MUSC Foundation for Research Development | Director/Board Member | ||
| AMAG PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer | |
| Bristol-Myers Squibb Pharma Co. | Corporate Officer/Principal | ||
| EPIZYME, INC. | Biotechnology | General Counsel | |
| University of Maryland School of Medicine | College/University | Doctorate Degree | |
Astex Pharmaceuticals, Inc.
 Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Pharmaceuticals: Major | Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
| Georgetown University Law Center | College/University | Graduate Degree | |
| Columbia Business School | College/University | Masters Business Admin | |
| EDITAS MEDICINE, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| Cardiff University School of Medicine | College/University | Doctorate Degree | |
| Boys & Girls Clubs of New Jersey | Director/Board Member | ||
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
| Clinical Biotechnology Research Institute | Director/Board Member | ||
Yumanity, Inc.
 Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Astex Pharmaceuticals Ltd.
 Astex Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Astex Pharmaceuticals Ltd. is a British company that provides drug development services. The company is based in Cambridge, UK. | Pharmaceuticals: Major | Director/Board Member | |
| SYNEOS HEALTH, INC. | Biotechnology | Director/Board Member | |
| SCHOLAR ROCK HOLDING CORPORATION | Biotechnology | Director/Board Member | |
| COMPASS PATHWAYS PLC | Biotechnology | Director/Board Member | |
| INVIVYD, INC. | Biotechnology | Corporate Officer/Principal | |
| The McQuade Center for Strategic Research & Development LLC | President | ||
| Emh Consulting Group, Inc. | President | ||
Hemab Therapeutics ApS
 Hemab Therapeutics ApS BiotechnologyHealth Technology Hemab Therapeutics ApS is a clinical-stage biotech company based in Copenhagen, Denmark and MA. The Danish company is focused on developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company's strategic guidance, Hemab 1-2-5tm, targets the development of 5 independent assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood-clotting disorders like Glanzmann thrombasthenia, Factor VII deficiency, Bernard Soulier syndrome, von Willebrand disease, and other serious disorders. | Biotechnology | Director/Board Member | |
| KINETA, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 41 |
| Verenigd Koninkrijk | 7 |
| Canada | 3 |
| Denemarken | 3 |
Sectoraal
| Health Technology | 26 |
| Consumer Services | 16 |
| Finance | 3 |
| Technology Services | 2 |
| Health Services | 2 |
Operationeel
| Director/Board Member | 46 |
| Independent Dir/Board Member | 16 |
| Corporate Officer/Principal | 11 |
| Chief Tech/Sci/R&D Officer | 10 |
| Director of Finance/CFO | 9 |
Sterkste connecties
| Insiders | |
|---|---|
| Brian Pereira | 23 |
| David Arkowitz | 20 |
| Robert McQuade | 14 |
| Akshay Vaishnaw | 11 |
| Bernadette Connaughton | 10 |
| John F. Weidenbruch | 9 |
| Elham Hershberger | 5 |
| David Oldach | 4 |
| Zachary Shriver | 4 |
| Todd Curtis | 1 |
| Harren Jhoti | 1 |
| Toshiki Sudo | 1 |
| Greg Babcock | 1 |
| Jean Bender | 1 |
| Jill Yarbrough | 1 |
- Beurs
- Insiders
- Chris Kiefer
- Bedrijfsconnecties
